GreenCell, Inc. (OTCBB: GCLL) reached up 11.36% in morning trading to $.98. GreenCell is engaged in a joint venture with SenCer Inc. to develop, commercialize and market SenCer's UltraTempTM ceramic composite materials for Home and Transportation applications. GreenCell has identified multiple industries with significant commercial applications with potential revolutionary results. Some of the many applications for this technology are SOFC Fuel Cells, Igniters, Braking, Oxygen Sensors, and Ceramic Heaters. GreenCell Inc. today announced the further milestone in the development of its UltraTemp-C technology. Through its Co-Owner, SenCer Inc., a program partially funded by the New York State Energy Research and Development Agency (NYSERDA) to develop a clean firing solution for silica sensitive products has been successful. A new form of High Temperature furnaces is now online for the manufacturing of igniters, fuel cells, and automotive sensors. This technology allows for a green, low cost manufacturing of the UltraTemp-C products of GreenCell. This will further the low, cost competitive nature of GreenCell's products and lead to higher manufacturing quality levels at a much lower cost. Silica contamination of critical fuel cell and sensor components will now be easily remedied. These High Temperature Systems will be available themselves for commercial sales.
BioCurex Inc. (OTCBB:BOCX) reached up 111.11% in morning trading to $.038 with 12M shares traded. BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF. BioCurex Inc. (OTCBB:BOCX.OB - News) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.
Marshall Edwards, Inc. (Nasdaq:MSHL) reached up 24.31% in morning trading to $1.79 with 550K shares traded. Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143. The second is a mitochondrial inhibitor program that includes lead candidate ME-344. Marshall Edwards, Inc. (Nasdaq:MSHL - News) announced today the initiation of a Phase I clinical trial of the Company's lead drug candidate ME-143 in patients with refractory solid tumors. The trial is being conducted in collaboration with the Sarah Cannon Research Institute in Nashville, Tennessee, following the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) last month.
MedeFile International, Inc. (PINK: MDFI) reached up 11.11% in morning trading to $.004 with 12M shares traded. MedeFile has developed and globally markets a proprietary, patient-centric, iPHR (Internet-enabled Personal Health Record) system for gathering, digitizing and organizing medical records so that individuals can have a comprehensive record of all of their medical visits. MedeFile's primary product is its web-based MedeFile solution, a highly secure system for gathering, maintaining, accessing and sharing personal medical records. Interoperable with most electronic medical record management systems marketed to the healthcare industry, the MedeFile solution is designed to gather all of its members' actual medical records and create a single, comprehensive Electronic Health Record (EHR) that is accessible 24 hours a day, seven days a week by the member and the member's authorized users on any web-enabled device (PC, cell phone, smartphone, e-reader) and portable MedeDrive unit. MedeFile International, Inc. (OTCQB: MDFI.PK - News) (Pinksheets: MDFI.PK - News) today announced that is has signed an agreement with ConnectCare3 (CC3), a revolutionary service designed to help seriously ill patients navigate the healthcare system.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com and affiliates have been compensation nine thousand dollars by a third party (Emerging Markets Consulting) for this current GCLL advertising and promotional program.
PennyTrader.com
is not a registered investment advisers or broker/dealer. PennyTrader.com makes
no recommendation that the purchase of securities of companies profiled in this
press release is suitable or advisable for any person or that an investment
such securities will be profitable. In general, given the nature of the micro
cap companies covered and the potential lack of an active trading market their
securities, investing in such securities is highly speculative and carries a
high degree of risk. For our full disclaimer go to CLICK
HERE
